IVS-1001 is under clinical development by Invectys and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IVS-1001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IVS-1001 overview

UCPVax is under development for the treatment of metastatic squamous cell non-small cell lung cancer, glioblastoma multiforme, lung adenocarcinoma, HPV positive cancers including advanced or metastatic anal cancer, head and neck squamous cell carcinoma, cervical and vulvar cancer and large cell carcinoma. The vaccine candidate is administered through subcutaneous route. It is composed of two peptides called UCP2 and UCP4 of 15 to 20 amino acids (universal cancer peptides-UCP) derived from telomerase reverse transcriptase (TERT) protein. The vaccine candidate is based on telomerase gene technology.

Invectys overview

Invectys is a biopharmaceutical company that develops immunotherapy to treat cancer. The company product pipeline includes INVAC-1, a DNA vaccine targeting Telomerase; Universal Cancer Peptide vaccine UCPVax. It offers products such as a human telomerase peptide-based vaccine; INMAB-1, a monoclonal antibody; and TelVet, dog telomerase DNA-based anti-cancer vaccine similar to INVAC-1. Invectys TelVet is developed for the treatment of pet cancers such as dog cancers. The company’s technology restores and mobilizes the anti-tumor ability of the immune system of cancer patients. Invectys is headquartered in Paris, Ile-de-France, France

For a complete picture of IVS-1001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.